Pegasus Partners’s Edwards Lifesciences EW Stock Holding History

Pegasus Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,226	Closed	-$212K	–	124
2022 Q2	$212K	Hold	2,226	–	–	0.04%	113
2022 Q1	$262K	Hold	2,226	–	–	0.05%	108
2021 Q4	$288K	Hold	2,226	–	–	0.05%	118
2021 Q3	$252K	Sell	2,226 -39	-2%	-$4.45K	0.05%	139
2021 Q2	$235K	Buy	+2,265	New	+$213K	0.05%	150
2021 Q1	–	Sell	-2,265	Closed	-$207K	–	165
2020 Q4	$207K	Buy	+2,265	New	+$188K	0.05%	143
2019 Q1	–	Sell	-6,726	Closed	-$343K	–	139
2018 Q4	$343K	Hold	6,726	–	–	0.1%	121
2018 Q3	$390K	Hold	6,726	–	–	0.09%	119
2018 Q2	$326K	Hold	6,726	–	–	0.08%	126
2018 Q1	$313K	Hold	6,726	–	–	0.07%	125
2017 Q4	$253K	Hold	6,726	–	–	0.05%	149
2017 Q3	$245K	Buy	6,726 +726	+12%	+$27.7K	0.06%	147
2017 Q2	$236K	Buy	+6,000	New	+$219K	0.06%	143
2016 Q4	–	Sell	-6,000	Closed	-$241K	–	113
2016 Q3	$241K	Buy	+6,000	New	+$226K	0.11%	108

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Pegasus Partners's EW Position: Q3 2022 in Review

Pegasus Partners sold out of Edwards Lifesciences (EW) in Q3 2022, closing a stake of 2,226 shares — an estimated $212K sold.

Pegasus Partners first reported a position in EW in Q3 2016 and held it in 14 quarters. The position peaked at $390K in Q3 2018. 1,246 funds tracked by Wall St. Rank hold EW as of Q3 2022.

Pegasus Partners reported no remaining Edwards Lifesciences position as of Q3 2022 after selling out during the quarter.
Pegasus Partners sold 2,226 Edwards Lifesciences shares in Q3 2022, an estimated $212K.
Pegasus Partners first reported a position in Edwards Lifesciences in Q3 2016 and held it in 14 quarters.
Pegasus Partners's Edwards Lifesciences position peaked at $390K in Q3 2018.
1,246 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2022.

Based on Pegasus Partners's 13F filing for Q3 2022, filed 10 Nov 2022.